Full Press Release Details
Adaptimmune Announces that SPEAR T-cell
Platform Delivers Initial Responses in Four Solid Tumor Indications
- Partial Responses seen in liver, melanoma,
gastro-esophageal junction, and head and neck cancers -
- Encouraging demonstration of the potential
of SPEAR T-cell platform across multiple targets and a range of solid tumors -
and OXFORDSHIRE, United Kingdom, January 13, 2020 -- Adaptimmune
Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported today, at the 38th JP Morgan Healthcare
Conference, two confirmed Partial Responses (PRs) - one in a patient with liver cancer and one in a patient with melanoma.
There are also two unconfirmed PRs - one in a patient with gastro-esophageal junction cancer and one in a patient with head
and neck cancer. These data further confirm the potential of Adaptimmune's SPEAR T-cell platform for patients with multiple
solid tumors. Data were previously reported showing compelling efficacy with ADP-A2M4 in synovial sarcoma.
"These responses demonstrate that our proprietary
SPEAR T-cell platform is clearly active and can overcome the challenges of treating a range of solid tumors with a T-cell
therapy product," said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer. "These are early results
and we need more patient data and durability information to determine which therapies to develop. Nonetheless, this is a
critical demonstration of the value of our SPEAR T-cell therapies for people with cancer and a validation of the
importance of our proprietary affinity engineering. I couldn't be prouder of the team at Adaptimmune, and we are
grateful to the investigators and patients who have put their faith in our treatment. We look forward to presenting data from
these trials at future scientific congresses."
Best overall responses:
There continues to be a favorable benefit:risk profile for all
products and indications under study. Most adverse events are consistent with those typically experienced by cancer patients undergoing
cytotoxic chemotherapy or other cancer immunotherapies. Adverse events (including cytokine release syndrome, neurotoxicity, and
prolonged cytopenias) occur at rates consistent with other T-cell therapies, and are managed in keeping with current guidelines.
Adaptimmune is a clinical-stage biopharmaceutical company focused
on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide
Enhanced Affinity Receptor) T-cell platform enables the engineering
of T-cells to target and destroy cancer across multiple solid tumors. For more information, please visit http://www.adaptimmune.com.
Adaptimmune Forward-Looking Statements
This release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain
risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated
by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities
and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization
processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from
those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our
Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 6, 2019, and our other
SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made
and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts:
S bastien Desprez - VP, Communications and Investor
Juli P. Miller, Ph.D. - Senior Director, Investor Relations